15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
15
Dec
2025
Biotech’s Future Will Be More Distributed
When we started our first biotech company, MediChem Life Sciences in the early 1990s in Chicago, there was nothing resembling a “biotech ecosystem” nearby. We had to build our own labs, figure out how to raise money and how to recruit a team of scientists and professionals. The universities in the Chicago area were more focused on basic science. The... Read More